BridgeBio Oncology Therapeutics, Inc. (BBOT) stock
BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.14−0.21 (-8.94%)
Close on Nov 13, 2026Market cap $171.57MP/E –Yield –
BridgeBio Oncology Therapeutics total assets
Total assets on the balance sheet at the end of each period.
BridgeBio Oncology Therapeutics's total assets was $346.22M at Sep 30, 2026. For fiscal 2025 it was $448.38M, up 172.9% from the year before.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $448.38M | +172.9% |
| FY2024 | Dec 31, 2024 | $164.30M | +49255.4% |
| FY2023 | Dec 31, 2023 | $332.89K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $346.22M | -28.6% |
| Q2 FY2026 | Jun 30, 2026 | $376.71M | +90.8% |
| Q1 FY2026 | Mar 31, 2026 | $417.65M | +113.4% |
| Q4 FY2025 | Dec 31, 2025 | $448.38M | +172.9% |
| Q3 FY2025 | Sep 30, 2025 | $484.79M | +152.1% |
| Q2 FY2025 | Jun 30, 2025 | $197.39M | +4.0% |
| Q1 FY2025 | Mar 31, 2025 | $195.68M | +4.3% |
| Q4 FY2024 | Dec 31, 2024 | $164.30M | +49255.4% |
| Q3 FY2024 | Sep 30, 2024 | $192.33M | – |
| Q2 FY2024 | Jun 30, 2024 | $189.87M | – |
| Q1 FY2024 | Mar 31, 2024 | $187.53M | – |
| Q4 FY2023 | Dec 31, 2023 | $332.89K | – |
See a number that looks wrong?